Imbria Pharmaceuticals
–
Boston, MA, 02298
... Part 2 of our Phase 2 trial, IMPROVE-DiCE, in patients with cardiometabolic HFpEF, is ongoing with topline results expected in early 2025. For additional information, please visit Position Overview This position manages overall clinical study ... - Apr 25